Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under Hemodialysis

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Sameiro Faria, Maria Do ^a,b   Kohlova, Michaela ^a   Ribeiro, Sandra ^a,c   Rocha Pereira, Petronila ^c,d   Teixeira, Laetitia ^a   Nascimento, Henrique ^a,c   Reis, Flávio ^e   Miranda, Vasco ^b   Bronze Da Rocha, Elsa ^a,c   Quintanilha, Alexandre ^a,c   Belo, Luís ^a,c   Costa, Elísio ^a,c   Santos Silva, Alice ^a,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b Frenesius Medical Care Nephrocare Maia SA   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; BILIRUBIN; GENOMIC DNA; GLUCURONOSYLTRANSFERASE 1A1; HEMOGLOBIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; TRANSFERRIN; GLUCURONOSYLTRANSFERASE; UGT1A1 ENZYME;

AGED; ARTICLE; CARDIOVASCULAR RISK; DNA DETERMINATION; END STAGE RENAL DISEASE; ERYTHROCYTE COUNT; FEMALE; GENE FREQUENCY; HEART PROTECTION; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HUMAN; IRON METABOLISM; LEUKOCYTE COUNT; LIPID ANALYSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; PROMOTER REGION; RENAL REPLACEMENT THERAPY; THROMBOCYTE COUNT; BLOOD; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; DEMOGRAPHY; GENETIC POLYMORPHISM; GENETICS; RISK FACTOR;

AGED; BILIRUBIN; CARDIOVASCULAR DISEASES; DEMOGRAPHY; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RENAL DIALYSIS; RISK FACTORS;

EID: 84935843965     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/175286     Document Type: Article

References (64)

1. R. N. Foley, P. S. Parfrey, J. D. Harnett, G. M. Kent, D. C. Murray, and P. E. Barre, "The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease, " The American Journal of Kidney Diseases, vol. 28, no. 1, pp. 53-61, 1996.
2. R. N. Foley, P. S. Parfrey, and M. J. Sarnak, "Clinical epidemiology of cardiovascular disease in chronic renal disease, " The American Journal of Kidney Diseases, vol. 32, no. 5, supplement 3, pp. S112-S119, 1998.
3. F. Locatelli, F. Conte, and D. Marcelli, "The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity-the experience of the Lombardy Dialysis Registry, " Nephrology Dialysis Transplantation, vol. 13, no. 7, pp. 1642-1644, 1998.
4. P. Gollapudi, J. W. Yoon, S. Gollapudi, M. V. Pahl, and N. D. Vaziri, "Leukocyte toll-like receptor expression in end-stage kidney disease, " The American Journal of Nephrology, vol. 31, no. 3, pp. 247-254, 2010.
5. R. Stocker, Y. Yamamoto, A. F. McDonagh, A. N. Glazer, and B. N. Ames, "Bilirubin is an antioxidant of possible physiological importance, " Science, vol. 235, no. 4792, pp. 1043-1046, 1987.
6. T.-W. Wu, K. P. Fung, J. Wu, C.-C. Yang, and R. D. Weisel, "Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins, " Biochemical Pharmacology, vol. 51, no. 6, pp. 859-862, 1996.
7. Z. Yesilova, M. Serdar, C. N. Ercin et al., "Decreased oxidation susceptibility of plasma lowdensity lipoproteins in patients with Gilbert's syndrome, " Journal of Gastroenterology and Hepatology, vol. 23, no. 10, pp. 1556-1560, 2008.
8. A. C. Bulmer, J. T. Blanchfield, I. Toth, R. G. Fassett, and J. S. Coombes, "Improved resistance to serum oxidation in Gilberts syndrome: a mechanism for cardiovascular protection, " Atherosclerosis, vol. 199, no. 2, pp. 390-396, 2008.
9. A.-C. Boon, C. L. Hawkins, K. Bisht et al., "Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status inGilbert syndrome, " Free Radical Biology and Medicine, vol. 52, no. 10, pp. 2120-2127, 2012.
10. J. Neuzil and R. Stocker, "Bilirubin attenuates radical-mediated damage to serumalbumin, " FEBS Letters, vol. 331, no. 3, pp. 281-284, 1993.
11. L. Vitek, M. Jirsa Jr., M. Brodanova et al., "Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels, " Atherosclerosis, vol. 160, no. 2, pp. 449-456, 2002.
12. L. Novotny and L. Vitek, "Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies, " Experimental Biology andMedicine, vol. 228, no. 5, pp. 568-571, 2003.
13. C. Mancuso, A. Bonsignore, E. di Stasio, A. Mordente, and R. Motterlini, "Bilirubin and S-nitrosothiols interaction: evidence for a possible role of bilirubin as a scavenger of nitric oxide, " Biochemical Pharmacology, vol. 66, no. 12, pp. 2355-2363, 2003.
14. T. Nakagami, K. Toyomura, T. Kinoshita, and S. Morisawa, "A beneficial role of bile pigments as an endogenous tissue protector: anti-complement effects of biliverdin and conjugated bilirubin, " Biochimica et BiophysicaActa, vol. 1158, no. 2, pp. 189-193, 1993.
15. M. Mayer, "Association of serum bilirubin concentration with risk of coronary artery disease, " Clinical Chemistry, vol. 46, no. 11, pp. 1723-1727, 2000.
16. Q.-H. Gong, J. W. Cho, T. Huang et al., "Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus, " Pharmacogenetics, vol. 11, no. 4, pp. 357-368, 2001.
17. P. J. Bosma, J. R. Chowdhury, C. Barker et al., "The genetic basis of the reduced expression of bilirubin UDPglucuronosyltransferase in Gilbert's syndrome, " New England Journal of Medicine, vol. 333, no. 18, pp. 1171-1175, 1995.
18. L. J. Horsfall, G. Rait, K. Walters et al., "Serum bilirubin and risk of respiratory disease and death, " Journal of the American Medical Association, vol. 305, no. 7, pp. 691-697, 2011.
19. I. Curjuric, M. Imboden, M. Adam et al., "Serum bilirubin is associated with lung function in a Swiss general population sample, " European Respiratory Journal, vol. 43, no. 5, pp. 1278-1288, 2014.
20. Y. H. Chen, S. C. Hung, andD. C. Tarng, "Serumbilirubin links UGT1A1∗28 polymorphism and predicts long-term cardiovascular events and mortality in chronic hemodialysis patients, " Clinical Journal of the American Society of Nephrology, vol. 6, no. 3, pp. 567-574, 2011.
21. A. C. Boon, A. C. Bulmer, J. S. Coombes, and R. G. Fassett, "Circulating bilirubin and defense against kidney disease and cardiovascular mortality: mechanisms contributing to protection in clinical investigations, " American Journal of Physiology. Renal Physiology, vol. 307, pp. F123-F136, 2014.
22. R. S. Hillman and K. A. Ault, "Clinical approach to anemia, " in Hematology in Clinical Practice, McGraw-Hill, New York, NY, USA, 3rd edition, 2002.
23. A. C. Bulmer, H. J. Verkade, and K.-H. Wagner, "Bilirubin and beyond: a review of lipid status in Gilberts syndrome and its relevance to cardiovascular disease protection, " Progress in Lipid Research, vol. 52, no. 2, pp. 193-205, 2013.
24. S. Jangi, L. Otterbein, and S. Robson, "The molecular basis for the immunomodulatory activities of unconjugated bilirubin, " International Journal of Biochemistry and Cell Biology, vol. 45, no. 12, pp. 2843-2851, 2013.
25. J.-S. Hahm, J. D. Ostrow, P. Mukerjee, and L. Celic, "Ionization and self-association of unconjugated bilirubin, determined by rapid solvent partition fromchloroform, with further studies of bilirubin solubility, " Journal of Lipid Research, vol. 33, no. 8, pp. 1123-1137, 1992.
26. G. R. Gourley, "Bilirubin metabolism and kernicterus, " Advances in Pediatrics, vol. 44, pp. 173-229, 1997.
27. N. Kaniwa, K. Kurose, H. Jinno et al., "Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (P229L) found in an African-American, "DrugMetabolismandDisposition, vol. 33, no. 3, pp. 458-465, 2005.
28. E. Beutler, T. Gelbart, and A. Demina, "Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?" Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 14, pp. 8170-8174, 1998.
29. M. Clementi, E. Di Gianantonio, L. Fabris et al., "Inheritance of hyperbilirubinemia: evidence for a major autosomal recessive gene, " Digestive and Liver Disease, vol. 39, no. 4, pp. 351-355, 2007.
30. C. Rodrigues, E. Costa, E. Vieira et al., "Bilirubin dependence on UGT1A1 polymorphisms, hemoglobin, fasting time and body mass index, "The American Journal of theMedical Sciences, vol. 343, no. 2, pp. 114-118, 2012.
31. C. Rodrigues, E. Vieira, R. Santos et al., "Impact of UGT1A1 gene variants on total bilirubin levels in Gilbert syndrome patients and in healthy subjects, " Blood Cells, Molecules, and Diseases, vol. 48, no. 3, pp. 166-172, 2012.
32. A. Jung, P. Korohoda, P. Krisper, and D. Schneditz, "Relationship between kinetics of albumin-bound bilirubin and watersoluble urea in extracorporeal blood purification, " Nephrology Dialysis Transplantation, vol. 27, no. 3, pp. 1200-1206, 2012.
33. H. J. Hwang and S. H. Kim, "Inverse relationship between fasting direct bilirubin and metabolic syndrome in Korean adults, " Clinica Chimica Acta, vol. 411, no. 19-20, pp. 1496-1501, 2010.
34. Y. Buyukasik, U. Akman, N. S. Buyukasik et al., "Evidence for higher red blood cell mass in persons with unconjugated hyperbilirubinemia and Gilberts syndrome, " The American Journal of theMedical Sciences, vol. 335, no. 2, pp. 115-119, 2008.
35. M. Wallner, A. C. Bulmer, C. Molzer et al., "Haem catabolism: a novel modulator of inflammation in Gilbert's syndrome, " European Journal of Clinical Investigation, vol. 43, no. 9, pp. 912-919, 2013.
36. K. H. Chan, R. L. OConnell, D. R. Sullivan et al., "Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, " Diabetologia, vol. 56, no. 4, pp. 724-736, 2013.
37. A. R. Kundur, A. C. Bulmer, and I. Singh, "Unconjugated bilirubin inhibits collagen induced platelet activation, " Platelets, vol. 25, no. 1, pp. 45-50, 2014.
38. K. Ohnaka, S. Kono, T. Inoguchi et al., "Inverse associations of serum bilirubin with high sensitivity C-reactive protein, glycated hemoglobin, and prevalence of type 2 diabetes in middle-aged and elderly Japanese men and women, " Diabetes Research and Clinical Practice, vol. 88, no. 1, pp. 103-110, 2010.
39. H.-J. Hwang, S.-W. Lee, and S.-H. Kim, "Relationship between bilirubin and C-reactive protein, " Clinical Chemistry and Laboratory Medicine, vol. 49, no. 11, pp. 1823-1828, 2011.
40. H. J. Hwang, S. W. Lee, and S. H. Kim, "Relationship between bilirubin and C-reactive protein, " Clinical Chemistry and Laboratory Medicine, vol. 49, no. 11, pp. 1823-1828, 2011.
41. G. Nanayakkara, T. Kariharan, L. Wang, J. Zhong, and R. Amin, "The cardio-protective signaling and mechanisms of adiponectin, " American Journal of Cardiovascular Disease, vol. 2, pp. 253-266, 2012.
42. M. T. Villarreal-Molina and B. Antuna-Puente, "Adiponectin: anti-inflammatory and cardioprotective effects, " Biochimie, vol. 94, no. 10, pp. 2143-2149, 2012.
43. G. Fantuzzi, "Adiponectin in inflammatory and immunemediated diseases, " Cytokine, vol. 64, no. 1, pp. 1-10, 2013.
44. A. Markaki, J. Kyriazis, K. Stylianou et al., "The role of serum magnesium and calcium on the association between adiponectin levels and all-cause mortality in end-stage renal disease patients, " PLoS ONE, vol. 7, no. 12, Article ID e52350, 2012.
45. N. Ohashi, A. Kato, T. Misaki et al., "Association of serum adiponectin levels with all-cause mortality in hemodialysis patients, " Internal Medicine, vol. 47, no. 6, pp. 485-491, 2008.
46. E. Abdallah, E. Waked, M. Nabil, and O. El-Bendary, "Adiponectin and cardiovascular outcomes among hemodialysis patients, " Kidney and Blood Pressure Research, vol. 35, no. 4, pp. 247-253, 2012.
47. H. Nascimento, E. Costa, S. Rocha et al., "Adiponectin and markers of metabolic syndrome in obese children and adolescents: impact of 8-month regular physical exercise program, " Pediatric Research, vol. 76, pp. 159-165, 2014.
48. M. L. V. Jacober, R. L. Mamoni, C. S. P. Lima, B. L. Dos Anjos, and H. Z. W. Grotto, "Anaemia in patients with cancer: role of inflammatory activity on iron metabolism and severity of anaemia, " Medical Oncology, vol. 24, no. 3, pp. 323-329, 2007.
49. H. A. Schwertner and J. R. Fischer Jr., "Comparison of various lipid, lipoprotein, and bilirubin combinations as risk factors for predicting coronary artery disease, " Atherosclerosis, vol. 150, no. 2, pp. 381-387, 2000.
50. H.-J. Hwang and S.-H. Kim, "Inverse relationship between fasting direct bilirubin and metabolic syndrome in Korean adults, " Clinica Chimica Acta, vol. 411, no. 19-20, pp. 1496-1501, 2010.
51. J. Jo, J. E. Yun, H. Lee, H. Kimm, and S. H. Jee, "Total, direct, and indirect serum bilirubin concentrations and metabolic syndrome among the Korean population, " Endocrine, vol. 39, no. 2, pp. 182-189, 2011.
52. R. Stocker, "Antioxidant activities of bile pigments, " Antioxidants and Redox Signaling, vol. 6, no. 5, pp. 841-849, 2004.
53. M. Wallner, R. Marculescu, D. Doberer et al., "Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in gilberts syndrome, " Clinical Science, vol. 125, no. 5, pp. 257-264, 2013.
54. Y. I. Miller, S.-H. Choi, L. Fang, and R. Harkewicz, "Tolllike receptor-4 and lipoprotein accumulation in macrophages, " Trends in Cardiovascular Medicine, vol. 19, no. 7, pp. 227-232, 2009.
55. C. Zoccali, F. Mallamaci, G. Tripepi et al., "Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease, " Journal of the American Society of Nephrology, vol. 13, no. 1, pp. 134-141, 2002.
56. S. Colman, R. Bross, D. Benner et al., "The Nutritional and Inflammatory Evaluation in Dialysis patients (NIED) study: overview of the NIED study and the role of dietitians, " Journal of Renal Nutrition, vol. 15, no. 2, pp. 231-243, 2005.
57. C. Delporte, P. van Antwerpen, L. Vanhamme, T. Roumeguere, and K. Zouaoui Boudjeltia, "Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies, "Mediators of Inflammation, vol. 2013, Article ID971579, pages, 2013.
58. F. Sztanek, I. Seres, M. Harangi et al., "Decreased paraoxonase 1(PON1) lactonase activity in hemodialyzed and renal transplanted patients. Anovel cardiovascular biomarker in end-stage renal disease, " Nephrology Dialysis Transplantation, vol. 27, no. 7, pp. 2866-2872, 2012.
59. M. Shekhanawar, S. M. Shekhanawar, D. Krisnaswamy et al., "The role of "paraoxonase-1 activity" as an antioxidant in coronary artery diseases, " Journal of Clinical and Diagnostic Research, vol. 7, no. 7, pp. 1284-1287, 2013.
60. Y. Ikeda, T. Suehiro, T. Itahara et al., "Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients, " Clinical Nephrology, vol. 67, no. 6, pp. 358-365, 2007.
61. A. Gugliucci, K. Kotani, and S. Kimura, "Paraoxonase 1 in chronic kidney failure, " Journal of Lipids, vol. 2012, Article ID 726048, 10 pages, 2012.
62. S. Ribeiro, M. Do Sameiro Faria, F. Mascarenhas-Melo et al., "Main determinants of PON1 activity in hemodialysis patients, " The American Journal of Nephrology, vol. 36, no. 4, pp. 317-323, 2012.
63. J. Marsillach, A. Martinez-Vea, L. Marcas et al., "Administration of exogenous erythropoietin β affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia, " Clinical and Experimental Pharmacology and Physiology, vol. 34, no. 4, pp. 347-349, 2007.
64. E. Costa, M. Lima, J. M. Alves et al., "Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy, " Journal of Clinical Immunology, vol. 28, no. 3, pp. 268-275, 2008.